Related Experiment Videos
Bone turnover and bone mineral density are independently related to selenium status in healthy euthyroid
Antonia Hoeg1, Apostolos Gogakos, Elaine Murphy
1Molecular Endocrinology Group, Imperial College London, 7N2a Commonwealth Building, Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom. graham.williams@imperial.ac.uk
Context:
Selenium status may have direct effects on bone and indirect effects through changes in thyroid hormone sensitivity.
Objective:
We hypothesized that variation in selenium status in healthy euthyroid postmenopausal women is associated with differences in bone turnover, bone mineral density (BMD) and fracture susceptibility.
Design:
The Osteoporosis and Ultrasound Study (OPUS) is a 6-yr prospective study of fracture-related factors.
Setting:
The study was comprised of a population-based cohort from five European cities.
Participants:
A total of 2374 postmenopausal women participated. Subjects with thyroid disease and nonthyroidal illness and those receiving drugs affecting thyroid status or bone metabolism were excluded, leaving a study population of 1144.
Interventions:
There were no interventions.
Main Outcome Measures:
We measured selenium (micrograms per liter); selenoprotein P (milligrams per liter); free T(4) (picomoles per liter); free T(3) (picomoles per liter); TSH (milliunits per liter); bone turnover markers; BMD; and vertebral, hip, and nonvertebral fractures.
Results:
Higher selenium levels were associated with higher hip BMD at study entry (β = 0.072, P = 0.004) and lower levels of bone formation (osteocalcin: β = -0.101, P < 0.001; procollagen type 1 N-terminal propeptide: β = -0.074, P = 0.013) and resorption markers (C-telopeptide of type 1 collagen: β = -0.058, P = 0.050; N-telopeptide of type 1 collagen: β = -0.095, P = 0.002). Higher selenoprotein P was associated with higher hip (β = 0.113, P < 0.001) and lumbar spine BMD (β = 0.088, P = 0.003) at study entry, higher hip BMD after the 6-yr follow-up (β = 0.106, P = 0.001) and lower osteocalcin (β = -0.077, P = 0.009), C-telopeptide of type 1 collagen (β = -0.075, P = 0.012), and N-telopeptide of type 1 collagen (β = -0.110, P < 0.001).
Conclusion:
Selenium status is inversely related to bone turnover and positively correlated with BMD in healthy euthyroid postmenopausal women independent of thyroid status.
Related Concept Videos
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:31Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:40Bone Remodeling
01:21Skeleton and Calcium Homeostasis